Quality assessment of a large multi-center flow cytometric dataset of acute myeloid leukemia patients-A EuroFlow study

Bras, A.E.; Matarraz, S.; Nierkens, S.; Fernandez, P.; Philippe, J.; Aanei, C.M.; ... ; EuroFlow Consortium (2022)

Article / Letter to editor

Simple Summary Flow cytometry allows detailed characterization of large numbers of cells and plays an important role in the diagnosis of acute myeloid leukemia. To facilitate analysis of flowcytometric data, reference databases of normal bone marrow samples and samples from acute myeloid leukemia patients, together with new software tools, are required. We here report on the building of a large database of acute myeloid leukemia patients (n = 1142) and 22 normal samples. We report on the quality assessment procedure used and its validation, discuss potential pitfalls, and provide possible solutions for avoiding such flaws in the construction of other databases. Our data show that obtaining and collecting reproducible flow cytometric data over time and across centers is feasible, but also that strict quality assessment remains crucial, even when standardized protocols for staining and instrument settings are being used in a multicenter setting. Flowcytometric analysis allows for detailed identification and characterization of large numbers of cells in blood, bone marrow, and other body fluids and tissue samples and therefore contributes to the diagnostics of hematological malignancies. Novel data analysis tools allow for multidimensional analysis and comparison of patient samples with reference databases of normal, reactive, and/or leukemia/lymphoma patient samples. Building such reference databases requires strict quality assessment (QA) procedures. Here, we compiled a dataset and developed a QA methodology of the EuroFlow Acute Myeloid Leukemia (AML) database, based on the eight-color EuroFlow AML panel consisting of six different antibody combinations, including four backbone markers. In total, 1142 AML cases and 42 normal bone marrow samples were included in this analysis. QA was performed on 803 AML cases using multidimensional analysis of backbone markers, as well as tube-specific markers, and data were compared using classical analysis employing median and peak expression values. Validation of the QA procedure was performed by re-analysis of >300 cases and by running an independent cohort of 339 AML cases. Initial evaluation of the final cohort confirmed specific immunophenotypic patterns in AML subgroups; the dataset therefore can reliably be used for more detailed exploration of the immunophenotypic variability of AML. Our data show the potential pitfalls and provide possible solutions for constructing large flowcytometric databases. In addition, the provided approach may facilitate the building of other databases and thereby support the development of novel tools for (semi)automated QA and subsequent data analysis.

• quality assessment
• AML
• flow cytometry
• EuroFlow

• All authors: Bras, A.E.; Matarraz, S.; Nierkens, S.; Fernandez, P.; Philippe, J.; Aanei, C.M.; Mello, F.V. de; Burgos, L.; Sluijs-Gelling, A.J. van der; Grigore, G.E.; Dongen, J.J.M. van; Orfao, A.; Velden, V.H.J. van der; EuroFlow Consortium
• Date: 2022-04-01
• Journal: Cancers
• Volume: 14
• Issue: 8
• DOI: doi:10.3390/cancers14082011